WallStSmart

Veradermics, Incorporated (MANE)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).

MANE

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 3/9

VRTX

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MANE.

VRTXUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$952.53

Current Price

$446.83

$505.70 discount

UndervaluedFair: $952.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MANE0 strengths · Avg: 0/10

No standout strengths identified

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.89B9/10

Large-cap with strong market position

Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

MANE4 concerns · Avg: 3.8/10
Price/BookValuation
9.2x4/10

Trading at 9.2x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MANE

MANE has a balanced fundamental profile.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : MANE

The primary concerns for MANE are Price/Book, Revenue Growth, EPS Growth.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

MANE profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

VRTX is growing revenue faster at 7.8% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VRTX scores higher overall (68/100 vs 25/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Veradermics, Incorporated

HEALTHCARE · BIOTECHNOLOGY · USA

Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company is headquartered in New Haven, Connecticut.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?